Indevus Pharma (IDEV) Announces NIH-Sponsored Study on PRO 2000 Shows Promise in HIV Prevention
Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that a National Institutes of Health-sponsored clinical study found that participating women who received PRO 2000, the Company's candidate vaginal microbicide for HIV prevention, had an approximately 30% lower risk of acquiring HIV infection than women who received a placebo or no vaginal product. All women participating in the study were offered free condoms and safer-sex counseling. This is the first trial to suggest any microbicide may prevent male-to-female sexual transmission of HIV although the beneficial effect did not reach statistical significance. The results will be presented today at the 16th Conference on Retroviruses and Opportunistic Infections in Montreal.
You May Also Be Interested In
- DISH Network (DISH) Sued by Networks for 'Commercial Skipping' Feature
- Watson Pharma (WPI) Confirms Patent Challenge on Testim from Auxilium
- IntercontinentalExchange (ICE) says daily crude volume hits record in May
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
